1995 - The Company is well poised to venture into new areas of activity which will propel it into achieving its projected goals.
1998 - The company is all set to realise it's laid-out expansion plans and gain substantially, both in sales volume and profits, with its proposed new product introductions, in the year.
1999 - The Company launched/re-launched a few products, which have been well received in the market.
- The Company raised funds to the tune of Rs.5 crores through issue of 5,00,000 16% Non-Convertible Secured Debentures of Rs. 100 each to Life Insurance Corporation of India, General Insurance Corporation of India (GIC) and four subsidiaries of GIC.
- The company is manufacturing off-patent drugs, where the entry barriers are relatively low.
- The company has entered into tie-ups to make a range of anti-oxidants and hormones which are expected to be launched in 1999-2000.
2000 - The Company is having in-house share transfer and related facilities at the Registered office New Delhi. The Company is entering into an agreement with NSDL and CDSL for
dematerialisation.
2004
-Company has issued a bonus shares in the ratio of 3:1.
2011
-The company has recommended a dividend of Rs. 0.50 per equity shares.
2013
-The company has recommended a dividend of Rs. 0.50 per equity shares.
-Mr. Raj Kumar Kapoor has been appointed as Compliance officer cum Company Secretary of the company.
2014
-The company has recommended dividend of Rs. 0.50/- per Equity share.
2024
-The Company has informed regarding Acquisition for signing Business Transfer Agreement for the purchase of India & Bhutan business of Yash Pharma Laboratories Pvt.Ltd.
-The Company Launches MemUp India's First Bioidentical Hormone Replacement Therapy in a Single Pill.
|